Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07468071) titled 'Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments' on March 9.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Novartis Pharmaceuticals
Condition:
Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer
Advanced Solid Tumors Harboring the KRAS G12C Mutation
Intervention:
Drug: Opnurasib
Drug: TNO155
Drug: trametinib
Biological: cetuximab
Rec...